XTalks

JUNE 1, 2022

Individuals at risk for developing osteomyelitis include those with a weak immune system, traumatic injury or wound, pressure injuries, artificial joints (like hip replacements) or metal implants in bone, blood infection and diabetes. due to a traffic accident), the more likely it is that an infection will develop.

Filler 98

Filler FDA Approval Production Marketing 98

The Pharma Data

NOVEMBER 30, 2020

30, 2020 – Nearly 15% of talc-based cosmetic products analyzed in a recent study contained asbestos. The voluntary testing method developed by industry is not sensitive enough to screen for asbestos when compared to electron microscopy, the group said. MONDAY, Nov. Food and Drug Administration does not require testing talc supplies.

Containment 52

Containment Production Cosmetics Contamination 52

Pharmaceutical Technology

MAY 10, 2023

Particle size is monitored in quality control as well as the development of active pharmaceutical ingredients (APIs). Some applications, such as powder inhalers for the treatment of lung diseases, require particle analysis as a critical aspect of their development.

Contamination 130

Contamination Filler Bioavailability Production 130

XTalks

MAY 14, 2024

SweetLeaf Xylitol, the latest innovation from Wisdom Natural Brands, marks a significant development in the natural sweeteners market. SweetLeaf Xylitol is distinct because it contains pure xylitol without any additional fillers or additives, making it a perfect one-to-one substitute for sugar in cooking, baking and beverages.

Filler 52

Filler Branding Production Containment 52

The Pharma Data

OCTOBER 22, 2021

Novartis blazoned moment that it has inked an original agreement to work its manufacturing capacity and capabilities to address the COVID-19 epidemic by expanding its support of the filler and finish of the Pfizer-BioNTech COVID-19 vaccine. The specifics will be bared when we conclude specific agreements.

Vaccination 52

Vaccination Vaccine Filler Manufacturing 52

The Pharma Data

DECEMBER 27, 2020

Current intraarticular anti-inflammatory treatments for OA have potentially toxic side effects and may lead to the destruction of cartilage filler proteins. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. SOUTH SAN FRANCISCO, Calif. About TLC599.

Trials 40

Trials Clinical Trials Clinical Trials Containment 40

The Pharma Data

NOVEMBER 4, 2020

(TSX: CTX) (OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house research & development (“R&D”) and manufacturing capabilities, today announced that it has entered into an exclusive agreement with Juyou-Biotechnology Co.

Licensing 40

Licensing Licensing Dermatology Production 40